Kanazawa University Research: Kanazawa University Invites Industry Collaboration for Cutting-Edge Bio-SPM Research
KANAZAWA, Japan, March 3, 2025 /PRNewswire/ -- Kanazawa University's Nano Life Science Institute (WPI-NanoLSI) is now accepting proposals from industry partners for collaborative research utilizing the world's most advanced bio-scanning probe microscope (Bio-SPM) technology. This initiative aims to foster groundbreaking industrial applications by leveraging WPI-NanoLSI's pioneering expertise in nano-life sciences.Advancing Industry Innovation with Bio-SPM TechnologyWPI-NanoLSI is dedicated to driving progress in nano-life sciences by advancing Bio-SPM technologies, including atomic resolution and 3D-AFM, high-speed AFM, scanning ion conductance microscopy (SICM), and cell measurement AFM. These techniques enable unprecedented visualization of dynamic biological and material phenomena at the nanoscale.Through this collaboration, industry researchers and engineers will have the opportunity to work alongside WPI-NanoLSI experts to explore innovative applications of Bio-SPM technology. The scope of research extends beyond biological samples, encompassing a wide range of materials and industrial applications. The advanced imaging capabilities of Bio-SPM offer the potential to capture nanometer-scale phenomena in motion—achievements that remain unattainable with conventional measurement techniques.
Why Partner with WPI-NanoLSI?With over 80 leading researchers and access to approximately 60 state-of-the-art Bio-SPM devices, WPI-NanoLSI has delivered significant scientific breakthroughs, including:- Structural analysis of microtubule interiors (Nano Lett., 2025) - https://nanolsi.kanazawa-u.ac.jp/en/highlights/32417/
- Real-time visualization of glutamate receptor molecule dynamics (ACS Nano, 2024) - https://nanolsi.kanazawa-u.ac.jp/en/highlights/31557/
- Observation of influenza virus genome synthesis processes (ACS Nano, 2024) - https://nanolsi.kanazawa-u.ac.jp/en/highlights/31433/
- Study of intrinsically disordered protein structures (Nat. Nanotechnology, 2020) - https://nanolsi.kanazawa-u.ac.jp/en/highlights/19908/
- Live-cell nanoscale imaging (Sci Adv, 2021) – https://nanolsi.kanazawa-u.ac.jp/en/highlights/22249/
For more details on the types of Bio-SPM and their applications, please visit the below link and click 'Overview of each Bio-SPM technology.'https://nanolsi.kanazawa-u.ac.jp/en/research/applications/bio-spm/
Application and Selection ProcessInterested companies can apply for collaborative research by specifying a WPI-NanoLSI researcher of choice or requesting assistance in finding a suitable research partner. Proposals will be evaluated based on their alignment with WPI-NanoLSI's Bio-SPM capabilities and the potential for impactful scientific and industrial advancements.Due to high demand, some applications may not be accepted despite meeting eligibility criteria.For more details on the application process, please visit the below link and click 'Application Guideline (for companies).'https://nanolsi.kanazawa-u.ac.jp/en/research/applications/bio-spm/
ContactResearch Collaboration Office,
WPI-NanoLSI, Kanazawa UniversityEmail : nanolsi_openf01@ml.kanazawa-u.ac.jp
About Kanazawa University and WPI-NanoLSIKanazawa University is a leading research institution dedicated to advancing science and technology on a global scale. The Nano Life Science Institute (WPI-NanoLSI) is at the forefront of nano-life science research, pioneering Bio-SPM technologies to explore biological structures and interactions with unprecedented detail.
Photo: https://mma.prnewswire.com/media/2631664/Kanazawa_University_BioSPMResearch.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/kanazawa-university-research-kanazawa-university-invites-industry-collaboration-for-cutting-edge-bio-spm-research-302389920.html
SOURCE Kanazawa University
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 hours ago
- Yahoo
MolecuLight® Imaging Significantly Improves Outcomes and Cuts Costs for Deep Sternal Wound Infections in Taiwan Study; Signals Expansion into Surgical Applications
PITTSBURGH and TAIPEI, June 12, 2025 /PRNewswire/ - MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for wound care, and its Taiwanese distributor, Healtdeva Company Ltd., congratulate researchers at Shuang-Ho Hospital in Taipei, Taiwan on their publication of groundbreaking findings using MolecuLight. The clinical study demonstrates the transformative impact of MolecuLight's i:X® device on the management of deep sternal wound infections (DSWI), showcasing significantly improved patient outcomes alongside cost savings and reduced burden on the healthcare system. The pivotal study, titled "Effects of adjuvant hyperbaric oxygen therapy and real-time fluorescent imaging on deep sternal wound infection: a retrospective study," published in the Journal of Wound Care (2025), revealed that incorporating MolecuLight's real-time fluorescence imaging into the treatment protocol for DSWI led to faster infection resolution, a dramatic reduction in antibiotic use and associated costs, shorter and less intensive hospital stays, and significantly lower rates of dangerous complications like reinfection and osteomyelitis compared to the standard of care with hyperbaric oxygen therapy (HBOT). Key findings that underscore the power of MolecuLight imaging: Significantly Improved Infection Control: MolecuLight-guided treatment increased the likelihood of white blood cell counts returning to normal within 7 days by 26-fold (72.7% vs. 9.1%) and C-reactive protein levels normalizing within 14 days by 7-fold (78.8% vs. 31.8%) compared to HBOT. Reduced Antibiotic Use and Costs: The MolecuLight group required antibiotics for a significantly shorter duration (22 days vs. 29.5 days), leading to nearly two-thirds lower antibiotic costs ($573.57 USD vs. $1643.78 USD). Faster Healing and Reduced Burden on Healthcare Systems: Patients treated with MolecuLight experienced ICU stays that were 70% shorter (3 days vs. 10 days) and achieved complete wound healing 20% faster (40 days vs. 50 days). Significantly Lower Risk of Complications: The use of MolecuLight imaging was associated with an 82% lower likelihood of in-hospital wound reinfection and an 86% lower risk of recurrent osteomyelitis, critical factors in long-term patient well-being and reduced healthcare expenditure. Enhanced Debridement Efficacy: The study highlights MolecuLight's ability to guide more precise and effective debridement, a cornerstone of successful wound management and infection control. "This study demonstrates that MolecuLight delivers tangible benefits in clinical wound management and also serves as a valuable teaching tool in our daily practice. The ability to visualize bacterial presence in real time allows us to more effectively guide younger physicians in understanding critical principles of infection control and intraoperative wound assessment. Moving forward, we intend to continue using this technology to enhance clinical decision-making and overall patient care," said study author Dr. Shun-Cheng Chang, from Shuang-Ho Hospital. "We are honored to introduce MolecuLight's advanced real-time fluorescence imaging technology to Taiwan," remarked Wei-Pin Hsieh, CEO of Healtdeva Company Ltd. "This innovation provides clinicians with a more efficient and accurate tool for assessing infections, opening new diagnostic perspectives in the management of complex wounds and post-operative care. We firmly believe that this technology will have a profound impact on improving patient outcomes and reducing overall healthcare costs." This study underscores the growing recognition of MolecuLight's significant utility beyond chronic wound care and its increasing adoption in critical surgical applications. The company's advanced imaging system, with its unique ability to visualize bacterial presence in real-time and guide targeted interventions, is gaining traction among surgeons looking to optimize outcomes and better manage post-operative complications in various surgical procedures, including the management of deep sternal wound infections (DSWI). "We wish to commend the researchers for their excellent work on this study," said Anil Amlani, CEO of MolecuLight. "These compelling results further validate the significant clinical and economic value of MolecuLight's technology, not only in chronic wound care but also in critical surgical applications. This study, along with our growing adoption in surgical settings, reflects the increasing recognition of our ability to provide critical, real-time information that empowers clinicians to make better decisions at the point of care, ultimately improving patient outcomes and reducing the burden of post-operative complications. We are proud to partner with Healtdeva Company to bring these benefits to patients in Taiwan." About MolecuLight Corp. is a privately owned medical imaging company with a global presence that manufactures and commercializes the MolecuLight i:X® and DX™ wound imaging devices. These are the only class II FDA-cleared point-of-care imaging devices for the real-time detection of elevated bacterial burden in wounds. They also provide accurate digital wound measurement for comprehensive wound management, supported by strong clinical evidence including over 100 peer-reviewed publications. About Healtdeva Company Company Ltd. was established in 1992 and is based in Taipei, Taiwan. Healtdeva Company Ltd. is a trusted distributor of medical technologies and healthcare solutions, with a well-established network across hospitals, clinics, and retail pharmaceuticals, advanced wound care, infection control, and preventive health. Healtdeva Company partners with global innovators to bring cutting-edge medical solutions to the Taiwanese market, driving clinical adoption and commercial success through localized expertise and strategic channel integration. View original content to download multimedia: SOURCE MolecuLight Corp.
Yahoo
13 hours ago
- Yahoo
Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025
CEO Amir Reichman to meet investors, pharma partners, and CDMO clients at global biotech conference JERUSALEM, June 12, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company developing inflammation and immunology (I&I) therapies and offering biologics CDMO services through its Scinai BioServices unit, today announced CEO Amir Reichman's participation in the BIO International Convention 2025 (June 16–19, Boston). The company will leverage the event to showcase its recent financial, operational, and strategic advances to prospective partners and investors. Recent SEPA Funding Enhances Operational Flexibility Last week, Scinai raised $1.38 million in gross proceeds through drawdowns under its Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors. The funding was executed at a volume-weighted average price of approximately $3.03 per ADS, reflecting a 3% discount to market, and was completed without any warrants, fees, or additional dilution mechanisms. The proceeds strengthen Scinai's balance sheet and provide additional capital to advance both its CDMO growth and R&D programs. The company is now accelerating supplier and partner engagements in order to advance its nanobody pipeline toward IND-enabling studies, while simultaneously working to expand CDMO capacity and marketing outreach. CDMO Business Scales Rapidly; 2025 Revenue Expected to Reach $2M Scinai's Q1 2025 financial results, released last month, showed rapid growth in CDMO revenues, nearly matching full-year 2024 revenues in just the first quarter. Based on strong demand and capacity utilization, the company has issued 2025 revenue guidance of approximately $2 million. Scinai currently anticipates its CDMO unit will reach breakeven by end of 2026, with long-term revenue potential of $12 million annually under a single production shift, scalable further with additional shifts. Cost Optimization Reduces Burn, Extends Runway, and Enhances Financial Stability Scinai recently implemented a targeted cost-reduction program expected to lower annual employment-related expenses by approximately $815,000. The initiative is aimed at reducing the company's operational burn rate, extending its financial runway, and improving overall financial resilience—while preserving the core scientific and operational talent critical to executing its CDMO and therapeutic development strategies. CEO Commentary and BIO 2025 Objectives "We're heading into BIO with momentum on all fronts, new funding, commercial traction in our CDMO business, and focused execution across our R&D programs," said Amir Reichman, CEO of Scinai. "We're proud of the progress we've made and are eager to explore new collaborations with pharma partners, CDMO clients, and investors." At BIO 2025, Mr. Reichman will hold meetings with pharmaceutical executives, institutional investors, and CDMO customers to present Scinai's recent achievements and discuss upcoming partnership opportunities. For meeting requests, please contact Scinai through the BIO partnering system or at info@ About Scinai Immunotherapeutics Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (nanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing biological drug development, analytical methods development, clinical cGMP manufacturing, and pre-clinical and clinical trial design and execution services for early stage biotech drug development projects. Company website: Company Contacts Investor Relations - Allele Capital Partners | +1 978 857 5075 | aeriksen@ Business Development | +972 8 930 2529 | bd@ Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical facts, are forward-looking statements. These forward-looking statements reflect management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of Scinai Immunotherapeutics Ltd. Risks and uncertainties include, but are not limited to; the risk that the Company will not be successful in advancing its CDMO growth or R&D programs; that the Company's CDMO will not reach breakeven by the end of 2026, or at all, or that long-term revenues of the CDMO unit will not increase as currently anticipated; the risk that the Company will be unable to remain compliant with the continued listing requirements of Nasdaq; lower than anticipated revenues of Scinai's CDMO business in 2025 and thereafter; failure to sign agreements with other potential clients of the CDMO business; a delay in the commencement and results of pre-clinical and clinical studies, including the Phase 1/2a study for psoriasis, the risk of delay in, Scinai's inability to conduct, or the unsuccessful results of, its research and development activities, including the contemplated in-vivo studies and a clinical trial; the risk that Scinai will not be successful in expanding its CDMO business or in-license other nanoAbs; the risk that Scinai may not be able to secure additional capital on attractive terms, if at all; the risk that the therapeutic and commercial potential of nanoAbs will not be met or that Scinai will not be successful in bringing the nanoAbs towards commercialization; the risk of a delay in the preclinical and clinical trials data for nanoAbs, if any; the risk that our business strategy may not be successful; Scinai's ability to acquire rights to additional product opportunities; Scinai's ability to enter into collaborations on terms acceptable to Scinai or at all; timing of receipt of regulatory approval of Scinai's manufacturing facility in Jerusalem, if at all or when required; and the risk that drug development involves a lengthy and expensive process with uncertain outcomes. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's Annual Report on Form 20-F filed with the Securities and Exchange Commission ("SEC") on May 7, 2025, and the Company's subsequent filings with the SEC. Scinai undertakes no obligation to revise or update any forward-looking statement for any reason. Logo: View original content: SOURCE Scinai Immunotherapeutics Ltd.
Associated Press
13 hours ago
- Associated Press
Arthrosi Presents Positive Long-Term Safety and Efficacy Data for Pozdeutinurad (AR882) at the European Alliance of Associations for Rheumatology (EULAR) Congress 2025
Data demonstrates that pozdeutinurad alone or in combination achieves significant reduction in sUA levels in patients with tophaceous gout up to 18 months of treatment Pozdeutinurad's long-term use was well tolerated and comparable to standard of care, with no incidences of elevated serum creatine or clinically significant liver function abnormalities SAN DIEGO, June 12, 2025 /PRNewswire/ -- Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, flares, and dissolve tophi in gout and tophaceous gout patients, today announced long term treatment data from the Phase 2 trial extension period evaluating patient outcomes up to 18 months of treatment with pozdeutinurad (formerly known as AR882). Detailed results will be presented at the European Alliance of Associations for Rheumatology (EULAR) Congress 2025 meeting, being held June 11-14, 2025, in Barcelona, Spain. 'The long-term data from our Phase 2 trial evaluating pozdeutinurad continues to build on the body of evidence differentiating it as a potentially transformative, best-in-class treatment option for patients with gout and tophaceous gout,' said Arthrosi's Chief Medical Officer Robert T. Keenan, MD, MPH, MBA. 'The significant and sustained reduction in sUA over 18 months observed in both the monotherapy and combination groups demonstrates better efficacy to standard of care alone. In addition, the high response rates of complete tophi resolution as well as rapid resolution of total urate crystal volume represent unprecedented quality of life improvements for patients living with gout. We have already fully enrolled the Phase 3 REDUCE 2 global trial and are rapidly enrolling patients in the ongoing Phase 3 REDUCE 1 trial.' The long term safety and efficacy data will be presented in both oral and poster presentations at EULAR. New Clinical Data for Pozdeutinurad Show: Presentation Details: Title: Sustained Efficacy of Pozdeutinurad (AR882): Long-Term Effect of a Novel and Selective URAT1 Inhibitor in Patients with Chronic Gouty Arthritis. Presenting Author: Robert Keenan, M.D., Chief Medical Officer of Arthrosi Therapeutics Format: Poster presentation Abstract Number: POS1307 Date and Time: Saturday, June 14, 2025, 10:00am-3:00pm CEST Title: Safety and Tolerability of Pozdeutinurad (AR882) Treatment following Long-term Dosing in Patients with Chronic Gouty Arthritis and Subcutaneous Tophi. Presenting Author: Robert Keenan, M.D., Chief Medical Officer of Arthrosi Therapeutics Format: Oral presentation Abstract Number: OP0300 Date and Time: Friday, June 13, 2025, 10:30am CEST About the AR882-203 Phase 2 Study: The Phase 2 study of pozdeutinurad (AR882) in patients with tophaceous gout was a six-month 1:1:1 randomized, global, placebo-controlled study of 42 patients with subcutaneous tophi. The mean baseline sUA among the participants ranged between 9.1-9.6 mg/dL. In the main treatment period, patients received a once daily dose of either 75 mg AR882, 50mg AR882 + allopurinol, or allopurinol up to 300mg. Serum uric acid levels (< 6, <5, <4, or <3 mg/dL) were evaluated monthly through month 6 and continued evaluated up to Month 18, and safety and tolerability were assessed throughout the study. Tophi measurements with calipers were completed every 4 weeks for 6 months and throughout the study. Patients were also imaged using Dual-Energy Computed Tomography (DECT), DECT a specialized imaging technique that is able to differentiate and identify uric acid crystals in the joints and soft tissue, allowing for quantifying uric acid crystal deposition and tophi at baseline, 6, 12, and 18 months. About Gout: In the U.S., an estimated 13 million individuals are diagnosed with gout, ~2 million of which have tophaceous gout. Gout is a form of inflammatory arthritis that can significantly diminish mobility, functionality, and overall quality of life. Gout emerges from the crystallization of uric acid within the joints and soft tissue, instigating painful flare-ups and chronic symptoms. The kidneys play a pivotal role in the process, as they are responsible for filtering out and excreting uric acid from the body. In over 90% of gout patients, underexcretion of uric acid results in the imbalanced and elevated sUA levels that can lead to the deposition of uric acid crystals. It's essential to monitor and manage sUA levels as part of comprehensive gout treatment and prevention strategies. About Arthrosi: Arthrosi Therapeutics, Inc., headquartered in San Diego, CA, is focused on developing pozdeutinurad (AR882), a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate levels, flares and tophi in patients with gout. Pozdeutinurad has demonstrated encouraging efficacy and safety compared to SOC in Phase 2 studies as well as impressive results in achieving complete resolution of tophi in a Phase 2b study. Arthrosi is currently advancing pozdeutinurad in a pivotal Phase 3 program. Media Contact: Shunqi Yan, PhD Founder & Chief Operating Officer [email protected] Investor Contact: Precision AQ Alex Lobo 212-698-8802 [email protected] View original content to download multimedia: SOURCE Arthrosi Therapeutics
